Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea

Trial Profile

Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Proof of concept
  • Acronyms JIKI
  • Most Recent Events

    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 18 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2015 Planned End Date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top